Attovia is creating a pipeline of biotherapeutics with an initial focus on immune-mediated disease and oncology. We leverage ATTOBODY, a novel biologics platform, to generate small format biparatopic binders that unlock the spatial aspect of target engagement.

The biparatopic binding mode of ATTOBODIES translates to picomolar affinity with glue-like off-rates, exquisite specificity, and accelerated target internalization. Their small format and modularity offer fast tissue penetration, ease of engineering into bispecifics, and tunable half-life from hours to weeks. Collectively, these properties of ATTOBODIES expand the addressable target and epitope universe across disease areas and can offer stronger efficacy, faster speed to response, and an improved safety profile compared to traditional approaches.

By utilizing our ATTOBODY technology, we will develop novel medicines that target unaddressed elements of disease, as well as offer better efficacy and tolerability. We envision a world where no patient is left behind.

Biotechnology

Life Sciences

Therapeutics

Attovia Therapeutics

Attovia Therapeutics' headquarters in Fremont, United States

Tao Fu

Sylvie Pham

Steven Chan

Hubert Chen

Veit Schmelmer

Zaneta Odrowaz

Petter Veiby

Luisa Salter - Cid

Hangjun Zhan

David King

Senior/executive Director, Head Of Regulatory Affairs

Description

People (19)

Tao Fu

Hangjun Zhan

Aaron Royston

Zaneta Odrowaz

Veit Schmelmer

Jing Zhang

Bobby Frazier

David Bellovin

Keegan Pham

Jin Wook Choi

Colman Ng

Yi Zheng

Ming Xu

Angie You

Mitchell Gold M.d.

Sogol Hekmatfar

Sylvie Pham

Thea Hawkins

Steven Chan

Jobs (1)

Senior/executive Director, Head Of Regulatory Affairs